AcroMeta Group Limited (SGX: 43F) has taken a significant step toward diversifying its portfolio by entering a non-binding term sheet with Macro HRD SG Pte. Ltd. (Macro), a Singapore-based management consultancy for the healthcare sector, to form a strategic partnership in the field of Ambient Temperature Cellular Logistics (ATCLS). The partnership involves AcroMeta acquiring a strategic stake in Macro-ATCLS Pte. Ltd., the company commercializing this emerging technology, and securing an option to obtain an exclusive licence to deploy the platform across Southeast Asia.
The ATCLS technology, licensed by Macro, aims to transform the transportation of living cells and temperature-sensitive biological materials by eliminating the need for conventional cold chains. Utilizing proprietary ambient-temperature preservation and reactivation technologies, supported by the Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance and process control, it enables dormant living cells to be transported at ambient temperatures and reactivated at the point of use. This innovation addresses critical challenges in the logistics of stem cells, CAR-T/immune-cell therapy, gene therapy, regenerative medicine, and organ transplantation, potentially reducing costs and geographic limitations associated with traditional methods.
The strategic importance of this move is underscored by market projections. The global cell-and-gene-therapy 3PL market is estimated at US$1.81 billion in 2025 and is projected to reach US$16.95 billion by 2035, representing a compound annual growth rate of 25.1%. Macro estimates a Serviceable Addressable Market (SAM) of approximately US$14.5 billion by 2032 for the ambient-addressable segments. These figures, provided by Macro's management and not independently verified, highlight the substantial growth opportunity.
Lawrence Toh, Executive Director of AcroMeta, commented, "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations, and we're excited about the potential to build a meaningful presence in bringing this technology into Southeast Asia."
The proposed exclusive licensing arrangement would grant AcroMeta rights to develop and commercialize ATCLS within agreed Southeast Asian territories, including the ability to appoint sub-licensees. This structure not only secures exclusive rights in key markets but also provides a first right to acquire additional territories, significantly expanding the Group's commercial reach. The Group intends to continue evaluating strategic opportunities to support long-term shareholder value, maintaining a focus on disciplined capital allocation.
AcroMeta, listed on the Catalist board of the Singapore Exchange since 2016, is primarily engaged in facility management services. This partnership marks a deliberate expansion into high-growth healthcare logistics, aligning with the broader industry trend toward specialized biopharmaceutical supply chains. As the demand for advanced therapies escalates, the ability to transport living cells without costly cryogenic infrastructure could be a game-changer, particularly in emerging markets like Southeast Asia where cold chain logistics are often challenging.
While the term sheet is non-binding and subject to due diligence and definitive agreements, the announcement signals AcroMeta's proactive approach to diversifying its revenue streams and capturing value in a niche with substantial upside. The collaboration with Macro, which brings together scientific, clinical, and technological expertise, positions AcroMeta to leverage cutting-edge innovation for long-term growth.
